Clinical trials: Circulatory Failure
Heart Failure, Congestive
A Method Validation Study for Evaluation of Novel Treatments Limiting Pulmonary Oedema in Cardiac Failure
Transient receptor potential vanilloid 4 (TRPV4) channel blockade may be promising in the treatment of pulmonary oedema and dyspnoea in heart failure (HF) and acute decompensated heart failure (ADHF) patients by re-establishing…
- Trial name
- NCT02135861
- Testing
- DCE-MRI scans, Gadobutrol
- Where
- United Kingdom
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Heart Failure, Congestive Heart Failure
Vasodilator Therapy for Heart Failure and Preserved Ejection Fraction
The main objective is to test the effect of prolonged therapy (24 weeks) with isosorbide dinitrate ± hydralazine on arterial wave reflections (primary endpoint).
- Trial name
- NCT01516346
- Testing
- Isosorbide Dinitrate, Isosorbide Dinitrate + Hydralazine
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Corporal Michael J. Crescenz VA Medical Center
Heart Failure
Right Ventricular (RV) Pacing in Early Post-operative Continuous Flow Left Ventricular Assist Device (LVAD)
Continuous right ventricular (RV) pacing demonstrates harm in patients with normal left ventricular (LV) function as well as in patients with cardiomyopathy and clinical heart failure.
- Trial name
- NCT01446796
- Testing
- Implantable Cardioverter-Defibrillator (subject's pre-existing ICD)
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Duke University
Heart Failure
Furoscix in Heart Failure Patients With Diuretic Resistance
This will be a randomized, open-label pilot study of 70 patients with and without diuretic resistance who were recently admitted and discharged for acute decompensated heart failure with and oral diuretic regimen testing whether…
- Trial name
- RESISTANCE-HF (NCT05528588)
- Testing
- Furoscix, Diuretic Therapy
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- University of Texas Southwestern Medical Center
End Stage Renal Disease, AV Fistula
Safety and Efficacy Study of the Venous Window Needle Guide to Access Arteriovenous (AV)Fistulae
The SAVE Study will evaluate the safety and efficacy of the Venous Window Needle Guide in achieving access of a deep, un-cannulatable arteriovenous fistula to complete hemodialysis as prescribed.
- Conditions
- End Stage Renal Disease, AV Fistula, Kidney Failure
- Trial name
- SAVE (NCT01471041)
- Testing
- Venous Window Needle Guide
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- Vital Access Corp.
Septic Shock
Treatment of Patients With Early Septic Shock and Bio-Adrenomedullin(ADM) Concentration > 70 pg/ml With ADRECIZUMAB
This is a double-blind, placebo-controlled, randomized, multicenter proof of concept and dose-finding phase II study using two doses of ADRECIZUMAB in patients with early septic shock and a bio-ADM plasma concentration at…
- Trial name
- AdrenOSS-2 (NCT03085758)
- Testing
- Adrecizumab
- Where
- 30 sites in Belgium, France and 2 more
- Volunteers
- 301 people
- Sponsor
- Adrenomed AG
Heart Failure
Percutaneous RVAD to Preemptively Treat Right Heart Failure Post-LVAD
Prior studies have shown that left ventricular assist device (LVAD) implantation commonly results in right ventricular failure (RVF).
- Trial name
- NCT04458103
- Testing
- Percutaneous RVAD
- Where
- United States
- Volunteers
- 161 people
- Sponsor
- Massachusetts General Hospital
Heart Failure
Dual-Site LV Pacing in CRT Non Responders: Multicenter Randomized Trial
Cardiac resynchronization therapy (CRT) is an effective treatment of heart failure (HF) refractory to optimal medical management, in presence of a depressed left ventricular (LV) ejection fraction and a wide QRS complex.
- Trial name
- V3 (NCT01059175)
- Testing
- Additional Endocardial or Epicardial LV Lead, CRT-P or CRT-D
- Where
- France
- Volunteers
- 84 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Abdominal Surgery, Respiratory Failure
Metabolites of Tramadol in the Postoperative Surgical Patients
Tramadol is opioid analgesic widely used to treat moderate to severe pain. It is metabolized by cytochrome CYP2D6 into two major metabolites: pharmacologically active metabolite O-desmethyltramadol (M1) and inactive…
- Conditions
- Abdominal Surgery, Respiratory Failure, Renal Failure, Liver Dysfunction
- Trial name
- METRAS (NCT04004481)
- Testing
- Postoperative analgesia using tramadol
- Where
- Croatia
- Volunteers
- 50 people
- Sponsor
- Osijek University Hospital
Sudden Cardiac Death, Sudden Cardiac Arrest
Heart Failure Optimization Study
This study is designed as a multi-center prospective observational study of newly diagnosed Heart Failure (HF) patients to test the hypothesis that additional Ejection Fraction (EF) recovery occurs between 90 and 180 days as…
- Conditions
- Sudden Cardiac Death, Sudden Cardiac Arrest, Heart Failure, Heart Failure Low Output
- Trial name
- HF-Opt (NCT03016754)
- Testing
- Wearable Cardioverter Defibrillator
- Where
- 67 sites in United States, Austria and 2 more
- Volunteers
- 602 people
- Sponsor
- Zoll Medical Corporation
Hypoplastic Left Heart Syndrome, Growth Failure
Comparison of Feeding Strategies for Hypoplastic Left Heart Syndrome Infants
The purpose of the study is to determine if a continuous feeding regimen as compared to an intermittent bolus feeding regimen leads to improved weight gain in infants with hypoplastic left heart syndrome (HLHS) after stage 1…
- Trial name
- NCT02657629
- Testing
- Continuous Feeding Regimen, Intermittent Bolus Feeding Regimen
- Volunteers
- 28 people
- Sponsor
- Columbia University
Multiple Organ Failure, Septic Shock
Early Metabolic Resuscitation for Septic Shock
This phase II trial studies how well early metabolic resuscitation therapy works in reducing multi-organ dysfunction in patients with septic shock.
- Conditions
- Multiple Organ Failure, Septic Shock, Severe Sepsis
- Trial name
- NCT03895853
- Testing
- Best Practice, early metabolic resuscitation
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- M.D. Anderson Cancer Center
Modified Release Oral Formulation, Left Ventricular Systolic Dysfunction
COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure
The primary objectives of this study are (i) to select an oral modified release (MR) formulation and dose of omecamtiv mecarbil for chronic twice daily (BID) dosing in adults with heart failure and left ventricular systolic…
- Conditions
- Modified Release Oral Formulation, Left Ventricular Systolic Dysfunction, Chronic Heart Failure, History of Chronic Heart Failure
- Trial name
- COSMIC-HF (NCT01786512)
- Testing
- Omecamtiv Mecarbil Matrix F1 Formulation, Omecamtiv Mecarbil Matrix F2 Formulation, Omecamtiv Mecarbil Swellable Core Technology F2
- Where
- 101 sites in United States, Australia and 11 more
- Volunteers
- 544 people
- Sponsor
- Cytokinetics
Sleep Disturbance, Heart Failure
Improving Sleep Quality in Heart Failure
Poor sleep quality is common in patients with heart failure. The limited available evidence intimates that improving sleep quality in patients with heart failure may improve morbidity and quality of life in this patient…
- Trial name
- NCT03307005
- Testing
- Zolpidem Tartrate
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Johns Hopkins University
Heart Failure, Heart Failure With Preserved Ejection Fraction
A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)
The main purpose of this study is to assess the efficacy and safety of LY3540378 in adults with worsening heart failure with preserved ejection fraction
- Trial name
- NCT05592275
- Testing
- LY3540378
- Where
- 137 sites in United States, Argentina and 10 more
- Volunteers
- 332 people
- Sponsor
- Eli Lilly and Company
Heart Failure
Intra-procedural Transthoracic EChocardiogram to Facilitate Left Bundle Branch Area Pacing (LBBAP)
The goal of this observational study is to learn more about whether or not the use of heart ultrasound during pacemaker implantation is helpful. The main questions this aims to answer are: 1.
- Trial name
- EC-LBBAP (NCT05646251)
- Testing
- Heart Ultrasound
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Geisinger Clinic
Atrial Fibrillation, Congestive Heart Failure
Investigational Device Exemption (IDE) Study for the Approval of Closed Loop Stimulation (CLS) and Cardiac Resyncronization Pacing Therapies (CRT) for the Treatment of Atrial Fibrillation (AF) With Ablate and Pace
The purpose of this study is to demonstrate the safety and effectiveness of biventricular pacing over conventional right ventricular pacing in patients with persistent or permanent, symptomatic atrial fibrillation undergoing…
- Trial name
- AVAIL (NCT00356057)
- Testing
- Protos DR/CLS and Stratos LV CRT pacemakers
- Where
- 10 sites in United States
- Volunteers
- 153 people
- Sponsor
- Biotronik, Inc.
Heart Failure, Diastolic, Diabetes Mellitus, Type 2
Evaluating Metabolic Mechanisms of Ertugliflozin in Diabetes & Heart Failure
This clinical trial will determine if subjects with heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes mellitus (DM2) receiving sodium-glucose cotransporter 2 (SGLTi2) inhibitor therapy (ertugliflozin)…
- Trial name
- EMMED-HF (NCT04071626)
- Testing
- Ertugliflozin 5 mg
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University Hospitals Cleveland Medical Center
Treatment of Hypovolemia and Shock
Gelatines in Pediatric PatientS
The aim of volume replacement is to compensate a reduction in the intravascular volume e.g. during surgery and to counteract hypovolemia in order to maintain hemodynamics and vital functions.
- Trial name
- GPS (NCT02495285)
- Testing
- Gelofusine 4%, Gelaspan 4%
- Where
- 11 sites in Bulgaria, Germany and 3 more
- Volunteers
- 601 people
- Sponsor
- B. Braun Melsungen AG
Chronic Heart Failure
Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure
The study will evaluate the efficacy and safety of both aliskiren monotherapy and aliskiren/enalapril combination therapy as compared to enalapril monotherapy, on morbidity and mortality in patients with chronic heart failure…
- Trial name
- ATMOSPHERE (NCT00853658)
- Testing
- Enalapril, Aliskiren
- Where
- 806 sites in United States, Argentina and 42 more
- Volunteers
- 7,064 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.